| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_289237dd1583cf0e158c2df13a6413c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0239a4bc2f5b942f5fb376590a0017c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_743e1398e92ddde1b3f874c3cf4ee699
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bba710e7aaa56d8ab15a910fcd3dc5f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y101-01028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y101-01027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2015-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc88ddfd91031618a2f7ae929f77a092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08c2ff49c3a1580341550932984f94db
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06781d5c689a5b20388d4470fe311044 |
| publicationDate |
2015-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015335674-A1 |
| titleOfInvention |
Ldh inhibitors as treatment for fibrosis and fibrotic-related disorders |
| abstract |
One aspect of the disclosure relates to methods of treating a fibrotic condition in an individual. The methods include administering to an individual having a fibrotic condition an effective amount of a lactic dehydrogenase (LDH) inhibitor, wherein the fibrotic condition involves an internal organ or tissue, or ocular tissue, and said administering is effective to treat the fibrotic condition. Methods of administration and pharmaceutical compositions and systems for practicing such methods are also disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10639313-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10772813-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3950060-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109996797-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112138159-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018053233-A1 |
| priorityDate |
2014-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |